Arbutus Biopharma Corp(ABUS)Earnings Date, History & Expected Move
Next report date, beat rate and options-implied move
ABUS is scheduled to report on Nov 11, 2026, usually before the market opens. Analysts expect EPS of -$0.02.
EPS: Actual vs Estimate
Reported earnings per share against the consensus estimate, last 12 quarters.
Green = beat or met, red = missed, amber = our data sources disagree on beat vs miss for that quarter.
Stock Reaction After Earnings
Close-to-close move in the first session that reflected each report.
Dashed lines mark the average actual move (±1.9%).
Did the stock rise after good news?
"Beat" means the company earned more than analysts expected. Here is what the stock did the next day.
In plain words: it beat expectations 3 times, but the stock still fell 1 of those 3 times.
- Aug '26Missed▼ -1.7%
- Mar '26Beat▲ +4.2%
- Nov '25Missed▼ -5.8%
- Aug '25Beat▲ +1.8%
- May '25Missed▼ -0.9%
- Nov '24Missed▼ -1.0%
- Aug '24Missed▲ +1.1%
- May '24Beat▼ -0.4%
- Nov '23Missed▼ -1.6%
Only reports with a clear beat or miss and a known price reaction are counted. A beat does not guarantee a gain.
Why did ABUS fall after beating earnings?
Beating or missing estimates is only part of the story. These are the measurable things that stand out for each surprising reaction.
ABUS beat EPS estimates in 3 quarters, and the stock still closed lower the next day 1 time.
- May 2, 2024EPS beat +6.7%stock -0.4% next day
- It opened 1.9% lower as soon as trading resumed.
Rose despite an EPS miss (1 of 6)
- Aug 1, 2024EPS missed -15.4%stock +1.1% next day
Nothing in the price and estimate numbers we track stands out for this one. Guidance and management comments are not part of our data.
These are patterns visible in estimates and prices, not confirmed causes. Information only, not investment advice.
Was ABUS's earnings move already priced in?
Stocks often move in the weeks before a report. This compares that run-up with what happened after the report.
“Month before” is the move over the 20 trading days up to the last close before the report. “Priced in” means the good news may already be in the price. A run-up of 5% or more is treated as large.
Before vs after each report
Grey: how the stock moved in the 20 trading days before the report. Green or red: how it moved the day after.
Past reports only: this shows what happened, not what will happen.
Does ABUS hold its opening gap after earnings?
A gap is how far the stock opens from the previous close. A gap fades when the stock gives back at least half of it by the end of the day.
In 9 reports ABUS opened at least 1% away from the previous close. It gave back half or more of that gap by the close 5 of 9 times (56%), and fully reversed 1 time. Gaps up faded 1 of 2; gaps down recovered 4 of 7.
- Aug 12, 2026HeldOpened -1.7%, closed -1.7%
- May 13, 2026FadedOpened +4.2%, closed 0.0%
- Mar 23, 2026HeldOpened +2.8%, closed +4.2%
- Nov 13, 2025HeldOpened -1.2%, closed -5.8%
- May 14, 2025HeldOpened -1.3%, closed -0.9%
- Nov 6, 2024FadedOpened -2.8%, closed -1.0%
- Aug 1, 2024ReversedOpened -3.4%, closed +1.1%
- May 2, 2024FadedOpened -1.9%, closed -0.4%
Gap = opening price vs the previous close. Close = the end of the first session that reflected the report. Reports without a clear opening time are left out.
ABUS earnings history
Last 12 reported quarters with the stock's reaction.
Swipe sideways to see every column →
| Report date | Time | EPS est. | EPS actual | Surprise | 1-day move | 3-day move |
|---|---|---|---|---|---|---|
| Aug 12, 2026 | Before open | -$0.03 | -$0.04 | -33.3% | -1.71% | 0.00% |
| May 13, 2026 | Before open | -$0.03 | $1.19 | sources differ | 0.00% | -1.62% |
| Mar 23, 2026 | Before open | -$0.05 | -$0.01 | +80.0% | +4.25% | +6.84% |
| Nov 13, 2025 | Before open | -$0.05 | -$0.06 | -20.0% | -5.79% | -6.20% |
| Aug 6, 2025 | Before open | -$0.09 | $0.01 | +111.1% | +1.76% | -0.29% |
| May 14, 2025 | Before open | -$0.15 | -$0.18 | -20.0% | -0.94% | -3.45% |
| Mar 27, 2025 | Before open | -$0.12 | -$0.10 | +16.7% | — | — |
| Nov 6, 2024 | Before open | -$0.13 | -$0.14 | -7.7% | -1.01% | -5.30% |
| Aug 1, 2024 | Before open | -$0.13 | -$0.15 | -15.4% | +1.06% | -3.98% |
| May 2, 2024 | Before open | -$0.15 | -$0.14 | +6.7% | -0.37% | +4.09% |
| Feb 29, 2024 | Before open | -$0.16 | -$0.16 | 0.0% | -2.78% | -5.90% |
| Nov 7, 2023 | Before open | -$0.15 | -$0.16 | -6.7% | -1.60% | -4.26% |
Consensus for the next report: EPS -$0.02, revenue $1.02M.
ABUS Earnings FAQ
Answers computed from Arbutus Biopharma Corp's reported history
ABUS is scheduled to report on Nov 11, 2026, usually before the market opens. Analysts expect EPS of -$0.02.
Over the last 11 quarters with a usable EPS surprise, ABUS beat the consensus estimate 4 times (36%), missed 6 and landed in line 1. 1 quarter where our data sources disagree on beat versus miss are shown but not counted.
Across its last 11 quarters with a measured reaction, ABUS moved an average of ±1.9% in the first session after reporting. It closed higher 27% of the time; the largest gain was 4.3% and the largest drop -5.8%.
Across its last 11 quarters with price data, ABUS moved an average of +4.4% in the 20 trading sessions before reporting and was higher in 64% of them. After a run-up of 3% or more (5 quarters), it fell the next day 60% of the time, averaging -1.4%. This describes past reports; it is not a forecast.
In 9 reports ABUS opened at least 1% away from the previous close. It gave back half or more of that gap by the close 5 of 9 times (56%), and fully reversed once. A fade means the opening move was partly undone during the first session.
How we calculate these numbers
Reported EPS and estimates come from Yahoo Finance; report times, upcoming dates and revenue come from Finnhub. The 1-day move is the close-to-close change over the first session that reflects the report (the report-day close for after-close reports, the prior close for pre-market reports); reactions are left blank when the report time is unknown or looks inconsistent. The expected move is the price of the nearest at-the-money straddle that expires after the report divided by the share price, shown only when the quotes are liquid. Quarters where the two data sources disagree on beat versus miss are shown but never counted. Information only, not investment advice.
Looking for more on ABUS?
Price charts, forecast, fundamentals and risk pages for ABUS are not on Tickzen yet. You can run a full stock analysis now.
Run the ABUS Stock Analyzer